People
Cancer patients aren’t getting the testing they need for precision medicine, partially because of pervasive confusion regarding terminology, according to a whitepaper released July 7 by the Consistent Testing Terminology Working Group.
BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Low-dose radiation therapy seems to improve outcomes for COVID-19 patients. At least a dozen clinical trials are underway throughout the world to further explore the benefits.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Diagnostics and therapeutics for Alzheimer’s disease are on the verge of becoming mainstream medicine. It’s about time, too.
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
What if you could get one vaccine that protects you against a wide spectrum of viruses, even viruses we haven’t discovered yet?
On Tuesday, the White House notified Congress and the United Nations of the decision. However, the withdrawal will not be immediate.
PRESS RELEASES